bodies, and those shared by ALS and FTLD such as TDP-43 pathology, co-occur in AD thereby rendering insights into biomarkers of PD, ALS and FTLD equally relevant to developing informative biomarkers for the onset and progression of AD (see Table 1 ). Further, the clinical and pathological overlap of AD with PD, ALS and FTLD make it attractive to be able to monitor biomarker evidence for the presence of AD pathology in the brains of patients with these other disorders. In addition, this special issue also includes chapters on biomarkers for schizophrenia, affective disorders and multiple sclerosis because the editors of this special issue and the authors of the chapters here envision many opportunities for advances in biomarker research in each of these areas of neuropsychiatric disease research to cross fertilize and stimulate progress in other areas of biomarker research including research on neurodegenerative disease biomarkers.
A leitmotif that emerges from the chapters throughout this special issue is the profound impact that the ongoing ''longevity revolution'' is having on populations worldwide. In fact, this unprecedented demographic ''sea change'' represents a seismic shift in populations around the world that is the most powerful driver for nearly all of the disorders covered in this special issue. Indeed, beginning in January of this year, 70 million members of the American ''baby boom'' generation (i.e. those individuals who were born between 1946 and 1964) started to turn 65 years old, and they will continue to pass this critical lifespan milestone (after which age the incidence of AD rises exponentially to double every 5 years) at a rate of one every 7 s for the next 20 years (Trojanowski et al., 2010a,b; Plassman et al., 2007; Hurd et al., 2007; Wimo and Prince, 2010; Hebert et al., 2001) . Moreover, just 20 years from now, in 2031, these baby boomers will begin to turn 85 years old, and it is estimated that among those individuals 85 years of age and older, about 50% will have AD (Trojanowski et al., 2010a,b; Plassman et al., 2007; Hurd et al., 2007; Wimo and Prince, 2010; Hebert et al., 2001) . Hence, tor those who have not yet noticed it, the epidemic of aging related neurodegenerative diseases is upon us, and there is no time to lose to forge an international plan to combat this epidemic before it becomes the most socially, economically and medically transformative natural disaster encountered by all populations worldwide to date.
The arguments for a clarion call to take global action to prevent this epidemic or reduce its impact on societies worldwide are straightforward to enumerate, and dramatic demographic changes 
